研究单位：[1]BeiGene[2]Sichuan Cancer Hospital & Institute Chengdu,Sichuan,China,610041[3]West China Hospital,Sichuan University Chengdu,China,610041[4]Affiliated Hospital of North Sichuan Medical College Nanchong,China,637000[5]Pindara Private Hospital Benowa,Queensland,Australia,4217[6]he Prince Charles Hospital Chermside,Queensland,Australia,4032[7]Mater Cancer Care Centre South Brisbane,Queensland,Australia,4101[8]John Flynn Private Hospital Tugun,Queensland,Australia,4224[9]Lyell McEwin Hospital Elizabeth Vale,South Australia,Australia,5112[10]Ballarat Health Services Ballarat,Victoria,Australia,3350[11]Monash Health Clayton,Victoria,Australia,3168
研究目的：
The purpose of the study is to compare progression-free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab in combination with placebo) as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and to compare overall survival (OS) between Arm A and Arm B.
